HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Federico, A Articles by Loguercio, C Search for Related Content PubMed PubMed Citation Articles by Federico, A Articles by Loguercio, C

A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations

Interuniversity Research Centre on Foods, Nutrition and Gastrointestinal Tract (CIRANAD), Unit of Gastroenterology, 2nd University of Naples, Naples, Italy

Correspondence to:
Correspondence to:
Professor C Loguercio
Interuniversity Research Centre on Foods, Nutrition and Gastrointestinal Tract (CIRANAD), Unit of Gastroenterology, 2nd University of Naples, Via Foria 58-80131 Naples, Italy; carmelina.loguercio@unina2.it

Keywords: silybin; non-alcoholic fatty liver disease; oxidative stress

The first 150 words of the full text of this article appear below.

Non-alcoholic fatty liver disease (NAFLD) may occur as an expression of a metabolic syndrome or in association with hepatitis C virus (HCV) chronic infection. The contemporaneous presence of NAFLD in this later group of patients may negatively affect the progression of fibrosis and the response to antiviral treatment.^1,2 It has been suggested that in the future a therapeutic approach to chronic liver disease would consist of a number of complementary approaches considering the multitude of pathogenic mechanisms.³ Silybin is a natural flavonoid that has been conjugated to vitamin E and phospholipids to improve its bioavailability, and antioxidant and antifibrotic activity.⁴

After approval of the ethics committee and informed consent, 85 outpatients were consecutively enrolled in the study: 59 were affected by primitive NAFLD (group A) and 26 by HCV related chronic hepatitis C in combination with NAFLD, all HCV genotype 1b, and non-responders to previous antiviral treatment (group B). All . . . [Full text of this article]